Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

H.C. Wainwright analyst increased the price target on shares of Verona Pharma (NASDAQ:VRNA) to $60 from the previous target of $42, maintaining a Buy rating on the shares.

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

HealthDay News — For patients with chronic obstructive pulmonary disease (COPD), budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with ...

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is needed to improve holistic patient care, according to a new editorial. The ...

Children who start smoking prior to age 15 have a 27% increased risk of developing chronic obstructive pulmonary disease (COPD) as adults, compared to those who started smoking later, researchers ...

Children who start smoking prior to age 15 have a 27% increased risk of developing chronic obstructive pulmonary disease (COPD) as adults, compared to those who started smoking later, researchers ...

Duan, MD, MS No link was found between Competitive Bidding Program implementation and changes in supplemental oxygen use or clinical outcomes in a population of Medicare beneficiaries with COPD ...